Contraception
Volume 79, Issue 4 , Pages 282-289 , April 2009

Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate

Received 30 April 2008 ,Revised 20 October 2008 ,Accepted 20 October 2008.

References 

  1. Thiboutot DM. Overview of acne and its treatment. Cutis. 2008;81(Suppl 1):3–7
  2. Webster GF. Acne vulgaris. State of the science. Arch Dermatol. 1999;135:1101–1102
  3. Mercurio MG, Gogstetter DS. Androgen physiology and the cutaneous pilosebaceous unit. J Gend Specif Med. 2000;3:59–63
  4. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology. 1998;196:148–152
  5. Tan JK, Degreef H. Oral contraceptives in the treatment of acne. Skin Therapy Lett. 2001;6:1–3
  6. O’Connell K, Westhoff C. Pharmacology of hormonal contraceptives and acne. Cutis. 2008;81(Suppl 1):8–12
  7. Schindler AE. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. Eur J Obstet Gynecol Reprod Biol. 2004;112:136–141
  8. Sitruk-Ware R. New progestogens for contraceptive use. Hum Reprod Update. 2006;12:169–178
  9. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today (Barc). 1995;31:517–536
  10. Oettel M, Gräser T, Hoffmann H, Moore C, Zimmermann H, Zimmermann T. The preclinical and clinical profile of dienogest: a short overview. In:  Nikolov R,  Hoffmann H,  Oettel M editor. Dienogest. A clinical study update on dienogest-containing products. Drugs Today (Barc). 35(Suppl C):1999;p. 3–12
  11. Pochi PE, Shalita AR, Strauss JS, et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24–25, 1990. J Am Acad Dermatol. 1991;24:495–500
  12. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96–102
  13. EMEA/CPMP/EWP/2158/99: Concept paper on the development of a Committee for Proprietary Medicinal Products (CPMP): points to consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. London, 1999.
  14. EMEA/CPMP/EWP/2158/99: Committee for Proprietary Medicinal Products (CPMP): guideline on the choice of the non-inferiority margin. London, 27 July 2005.
  15. Zimmermann T, Wisser KH, Dietrich H. The effects of Valette® on skin and hair: a post-marketing surveillance study. Int J Clin Pract. 2000;54:85–91
  16. Moore C, Luderschmidt C, Moltz L, Oettel M, Klinger G, Schreiber G. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. In:  Nikolov R,  Hoffmann H,  Oettel M editor. Dienogest. A clinical study update on dienogest-containing products. Drugs Today (Barc). 35(Suppl C):1999;p. 69–78
  17. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception. 2006;73:23–29
  18. Golbs S, Klinger G, Moore C, Walter F, Mellinger U. Beeinflussung klinisch-chemischer und hämatologischer Parameter nach Verabreichung von MP 2000 über 6 Zyklen an gesunden Probandinnen im Rahmen einer Pilot-Studie. In:  Teichmann AT editors. Dienogest. Präklinik und Klinik eines Gestagens. 2nd ed.. Berlin: Walter de Gruyter; 1995;p. 191–201
  19. Wiegratz I, Lee JH, Kutschera E, et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception. 2002;65:223–229
  20. Moore C, Feichtinger W, Klinger G, et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. In:  Nikolov R,  Hoffmann H,  Oettel M editor. Dienogest. A clinical study update on dienogest-containing products. Drugs Today (Barc). 35 (Suppl C):1999;p. 53–68

☆ This study was funded by Schering (Berlin, Germany; now Bayer Schering Pharma).

PII: S0010-7824(08)00491-5

doi: 10.1016/j.contraception.2008.10.010

Contraception
Volume 79, Issue 4 , Pages 282-289 , April 2009

Article Tools

* Image Usage & Resolution